Skip to main
LENZ
LENZ logo

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc. is focused on developing its topical eye drop treatment, aceclidine, for presbyopia, demonstrating significant patient benefits in trials, with 84% of participants achieving at least a 4-line gain in near vision. The probability-adjusted revenue projections indicate a substantial growth trajectory, moving from an anticipated $7.2 million in 2025 to approximately $421.2 million by 2034, highlighting the market potential for aceclidine in treating presbyopia. Notably, aceclidine's selective targeting of the iris sphincter muscle while avoiding myopic shifts positions it as a promising therapy with durable efficacy and rapid visual improvements.

Bears say

LENZ Therapeutics Inc reported a significant net loss of $10.3 million, or $0.40 per share, for the second quarter of 2024, highlighting the company's ongoing financial challenges. The investment outlook is further dampened by the potential failure of its developmental candidates to meet peak commercial revenue estimates, alongside concerns about the ability to secure necessary capital resources and the continued viability of program development. Additionally, complications associated with existing treatment options, such as pilocarpine, suggest market penetration obstacles and could hinder the company's growth in the ophthalmic pharmaceutical sector.

LENZ has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 5 analysts, LENZ has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.